Arch Biopartners Inc. develops therapeutics for acute kidney injury and chronic kidney disease. Company news centers on LSALT peptide for cardiac surgery-associated acute kidney injury, cilastatin for drug-toxin-related acute kidney injury, and a chronic kidney disease platform tied to interleukin-32.
Recurring updates include clinical trial agreements, ethics and operational approvals, hospital site activity, patient recruitment and dosing milestones, drug-product manufacturing for cilastatin, patent filings connected with the CKD platform, and board governance changes. The company’s disclosures also describe acute kidney injury mechanisms such as ischemia-reperfusion injury, nephrotoxic pharmaceuticals, and inflammation-related kidney damage.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.